Beijing Tiantan Biological Products (SHSE:600161) LT-Debt-to-Total-Asset: 0.00 (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

SHSE:600161 Beijing Tiantan Biological Products Corp Ltd SHSE:600161
75 GF Score
Price ¥12.67
GF Value ¥23.94
Valuation Significantly Undervalued
! 3 Warning Signs
View Full Analysis

What is Beijing Tiantan Biological Products LT-Debt-to-Total-Asset?

Beijing Tiantan Biological Products SHSE:600161 -2.16% 75 LT-Debt-to-Total-Asset is 0.00 as of Mar. 2026. GuruFocus rates SHSE:600161 with a GF Score™ of 75/100 and a GF Value™ of ¥23.94 (Significantly Undervalued). The stock has 3 warning signs investors should review.

LT Debt to Total Assets is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. It is calculated as a company's Long-Term Debt & Capital Lease Obligationdivide by its Total Assets. Beijing Tiantan Biological Products's long-term debt to total assests ratio for the quarter that ended in Mar. 2026 was 0.00.

Beijing Tiantan Biological Products's long-term debt to total assets ratio declined from Mar. 2025 (0.01) to Mar. 2026 (0.00). It may suggest that Beijing Tiantan Biological Products is progressively becoming less dependent on debt to grow their business.

Beijing Tiantan Biological Products  (SHSE:600161) LT-Debt-to-Total-Asset Explanation

LT Debt to Total Asset is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. A year-over-year decrease in this metric would suggest the company is progressively becoming less dependent on debt to grow their business.

Beijing Tiantan Biological Products LT-Debt-to-Total-Asset Related Terms

Beijing Tiantan Biological Products LT-Debt-to-Total-Asset Historical Data

* Premium members only.

The historical data trend for Beijing Tiantan Biological Products's LT-Debt-to-Total-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Beijing Tiantan Biological Products LT-Debt-to-Total-Asset Chart

Beijing Tiantan Biological Products Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
LT-Debt-to-Total-Asset
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.03 0.02 0.00 0.00 0.00

Beijing Tiantan Biological Products Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
LT-Debt-to-Total-Asset Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.01 0.01 0.00 0.00 0.00
SHSE:600161
75GF Score
Beijing Tiantan Biological Products Corp Ltd SHSE:600161
LT-Debt-to-Total-Asset is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Beijing Tiantan Biological Products LT-Debt-to-Total-Asset Calculation

Beijing Tiantan Biological Products's Long-Term Debt to Total Asset Ratio for the fiscal year that ended in Dec. 2025 is calculated as

LT Debt to Total Assets (A: Dec. 2025 )=Long-Term Debt & Capital Lease Obligation (A: Dec. 2025 )/Total Assets (A: Dec. 2025 )
=68.007/16583.016
=0.00

Beijing Tiantan Biological Products's Long-Term Debt to Total Asset Ratio for the quarter that ended in Mar. 2026 is calculated as

LT Debt to Total Assets (Q: Mar. 2026 )=Long-Term Debt & Capital Lease Obligation (Q: Mar. 2026 )/Total Assets (Q: Mar. 2026 )
=70.94/16675.421
=0.00

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about LT-Debt-to-Total-Asset →
What does a LT-Debt-to-Total-Asset of 0.00 mean?
Beijing Tiantan Biological Products (SHSE:600161) has a LT-Debt-to-Total-Asset of 0.00 as of Mar. 2026. Long-term Debt to Total Asset ratio is the ratio of total long-term debt to total assets. View historical data on Beijing Tiantan Biological Products and its competitors.
Is Beijing Tiantan Biological Products' LT-Debt-to-Total-Asset too high?
Beijing Tiantan Biological Products' current LT-Debt-to-Total-Asset is 0.00. Overall, Beijing Tiantan Biological Products has a GF Score™ of 75/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Beijing Tiantan Biological Products' LT-Debt-to-Total-Asset compare to VRTX and REGN?
Beijing Tiantan Biological Products' LT-Debt-to-Total-Asset of 0.00 can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good LT-Debt-to-Total-Asset for a Biotechnology company?
A good LT-Debt-to-Total-Asset depends on the Biotechnology industry context. However, LT-Debt-to-Total-Asset should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high LT-Debt-to-Total-Asset mean?
A high LT-Debt-to-Total-Asset can signal that a stock is expensive relative to its fundamentals. Long-term Debt to Total Asset ratio is the ratio of total long-term debt to total assets. View historical data on Beijing Tiantan Biological Products and its competitors. Beijing Tiantan Biological Products's current LT-Debt-to-Total-Asset is 0.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Beijing Tiantan Biological Products stock overvalued right now?
Based on GuruFocus' analysis, Beijing Tiantan Biological Products (SHSE:600161) is currently considered Significantly Undervalued. The stock's GF Value™ is ¥23.94, compared to a current price of ¥12.67 — trading 47.1% below its estimated fair value. The current LT-Debt-to-Total-Asset is 0.00. Beijing Tiantan Biological Products' overall GF Score™ is 75/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is LT-Debt-to-Total-Asset calculated?
LT-Debt-to-Total-Asset is calculated from a company's financial statements. For Beijing Tiantan Biological Products (SHSE:600161), the current LT-Debt-to-Total-Asset is 0.00 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Beijing Tiantan Biological Products (SHSE:600161) Overvalued in 2026?

Based on GuruFocus' analysis, Beijing Tiantan Biological Products stock appears to be undervalued. The current stock price of ¥12.67 is trading 47.1% below its estimated GF Value™ of ¥23.94. GuruFocus considers Beijing Tiantan Biological Products to be Significantly Undervalued.

Key valuation signals for SHSE:600161:

  • LT-Debt-to-Total-Asset: 0.00
  • GF Value™: ¥23.94 vs. price of ¥12.67 (47.1% below fair value)
  • GF Score™: 75/100 with 3 warning signs

No single metric tells the full story. See the SHSE:600161 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Beijing Tiantan Biological Products Business Description

Address No. 2, Shuangqiao Road, Chaoyang District, Beijing, CHN, 100024
Beijing Tiantan Biological Products Corp Ltd uses healthy human plasma and specifically immunized human plasma as raw materials and adopts genetic recombination technology to develop and produce blood products and engage in the blood product business. The company's main products include human albumin, human immunoglobulin (pH4) for intravenous injection, human hepatitis B immunoglobulin, human immunoglobulin, human rabies immunoglobulin, human histamine immunoglobulin, and others.
75GF Score

Get the complete analysis for SHSE:600161

LT-Debt-to-Total-Asset is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

¥12.67
Price
¥23.94
GF Value